EUVIMEDSkopri EUVIMED
EditorialKommentar

Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV ‐infected individuals treated with pegylated interferon—implications for stopping rules and the HBV cure programme

James Lok iD

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.18142 ↗

At a glance

Editorial in Alimentary Pharmacology & Therapeutics, 2024. Written by James Lok. Institution: Institute of Liver Studies, King's College Hospital, London, UK. Major MEDLINE topics: Antiviral Agents. Cited 1 times so far (Crossref); 10 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

LINKED CONTENT This article is linked to Chen et al papers. To view these articles, visit https://doi.org/10.1111/apt.18131 and https://doi.org/10.1111/apt.18174

Subjects

MeSH terms (MEDLINE)

Antiviral AgentsHumansB7-H1 AntigenPolyethylene GlycolsProgrammed Cell Death 1 ReceptorInterferon-alphaHepatitis B, ChronicHepatitis B virusHepatitis B

Substances

Antiviral AgentsB7-H1 AntigenPolyethylene GlycolsProgrammed Cell Death 1 ReceptorInterferon-alphaCD274 protein, human

Authors and institutions

  • Institute of Liver Studies, King's College Hospital, London, UK.

ORCID profiles: James Lok

Cite

APA

Lok, J. (2024). Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV ‐infected individuals treated with pegylated interferon—implications for stopping rules and the HBV cure programme. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18142

Vancouver

Lok J. Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV ‐infected individuals treated with pegylated interferon—implications for stopping rules and the HBV cure programme. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18142

BibTeX
@article{Lok2024,
  author = {Lok, James},
  title = {Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV ‐infected individuals treated with pegylated interferon—implications for stopping rules and the HBV cure programme},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.18142}
}
Start for free →